BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34267503)

  • 1. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations.
    Leader LD; O'Connell M; VandenBerg A
    Pharmacotherapy; 2019 Nov; 39(11):1105-1112. PubMed ID: 31514247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brexanolone for postpartum depression.
    Hutcherson TC; Cieri-Hutcherson NE; Gosciak MF
    Am J Health Syst Pharm; 2020 Feb; 77(5):336-345. PubMed ID: 32073124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
    Meltzer-Brody S; Colquhoun H; Riesenberg R; Epperson CN; Deligiannidis KM; Rubinow DR; Li H; Sankoh AJ; Clemson C; Schacterle A; Jonas J; Kanes S
    Lancet; 2018 Sep; 392(10152):1058-1070. PubMed ID: 30177236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
    Kanes S; Colquhoun H; Gunduz-Bruce H; Raines S; Arnold R; Schacterle A; Doherty J; Epperson CN; Deligiannidis KM; Riesenberg R; Hoffmann E; Rubinow D; Jonas J; Paul S; Meltzer-Brody S
    Lancet; 2017 Jul; 390(10093):480-489. PubMed ID: 28619476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
    Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
    JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression.
    Barnes KN; Vogl CM; Nelson LA
    Ann Pharmacother; 2024 Jul; 58(7):728-734. PubMed ID: 37876133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression.
    Cooper MC; Kilvert HS; Hodgkins P; Roskell NS; Eldar-Lissai A
    CNS Drugs; 2019 Oct; 33(10):1039-1052. PubMed ID: 31642037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis.
    Winslow M; White E; Rose SJ; Salzer E; Nemec EC
    Int J Clin Pharm; 2024 Jun; 46(3):590-601. PubMed ID: 38489051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.
    Frieder A; Fersh M; Hainline R; Deligiannidis KM
    CNS Drugs; 2019 Mar; 33(3):265-282. PubMed ID: 30790145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.
    Zou J; Yang L; Yang G; Gao J
    Psychiatry Res; 2023 Oct; 328():115450. PubMed ID: 37683318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis.
    Li Z; Wu Q; Peng P; Wu M; Liu S; Liu T
    Psychiatry Res; 2024 Jan; 331():115640. PubMed ID: 38029628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression.
    Powell JG; Garland S; Preston K; Piszczatoski C
    Ann Pharmacother; 2020 Feb; 54(2):157-163. PubMed ID: 31476884
    [No Abstract]   [Full Text] [Related]  

  • 14. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression.
    Kanes SJ; Colquhoun H; Doherty J; Raines S; Hoffmann E; Rubinow DR; Meltzer-Brody S
    Hum Psychopharmacol; 2017 Mar; 32(2):. PubMed ID: 28370307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexanolone: A Novel Drug for the Treatment of Postpartum Depression.
    Patatanian E; Nguyen DR
    J Pharm Pract; 2022 Jun; 35(3):431-436. PubMed ID: 33302791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zuranolone: A Narrative Review of a New Oral Treatment for Postpartum Depression.
    Hitt EM
    Clin Ther; 2024 May; 46(5):433-438. PubMed ID: 38697873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States.
    O'Callaghan L; Chertavian E; Johnson SJ; Ferries E; Deligiannidis KM
    J Med Econ; 2024; 27(1):492-505. PubMed ID: 38465615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zuranolone for the Treatment of Postpartum Depression.
    Deligiannidis KM; Meltzer-Brody S; Maximos B; Peeper EQ; Freeman M; Lasser R; Bullock A; Kotecha M; Li S; Forrestal F; Rana N; Garcia M; Leclair B; Doherty J
    Am J Psychiatry; 2023 Sep; 180(9):668-675. PubMed ID: 37491938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in treatment for postpartum major depressive disorder.
    Amodeo G; Laurenzi PF; Santucci A; Cuomo A; Bolognesi S; Goracci A; Rossi R; Beccarini Crescenzi B; Neal SM; Fagiolini A
    Expert Opin Pharmacother; 2020 Oct; 21(14):1685-1698. PubMed ID: 32584616
    [No Abstract]   [Full Text] [Related]  

  • 20. Brexanolone (Zulresso) for postpartum depression.
    Med Lett Drugs Ther; 2019 May; 61(1571):68-70. PubMed ID: 31169804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.